

Neurotech

25 October 2017

ALLOTMENT OF PLACEMENT SHARES

The Directors of Neurotech International Limited (“Neurotech” or the “Company”) (ASX: NTI) advise that the Company has allotted a total of 13,205,266 ordinary fully paid shares at a price of 20 cents per share (New Shares) pursuant to a placement announced on Monday, 16 October 2017 (Placement). The Placement of the first tranche raised \$2.641 million and was made to professional and sophisticated investors, pursuant to section 708 of the Corporations Act 2001(Cth) and utilised the Company’s current placement capacity under Listing Rules 7.1 and 7.1A of the ASX Listing Rules. The second tranche of the Placement is to be made subject to shareholder approval to be sought at the forthcoming AGM.

In accordance with Listing Rules 7.1A.4(b) and 3.10.5A, the Company makes the following disclosures in respect of the first tranche placement:

(a) The issued capital of Neurotech prior to the Placement was 59,548,054 ordinary fully paid shares (plus 28,487,058 restricted ordinary fully paid shares) and 10,894,390 unlisted options. The issued capital of Neurotech following completion of the Placement is now:

- 72,753,320 ordinary fully paid shares
- 28,487,058 restricted ordinary fully paid shares
- 67,619,235 unlisted options

(b) The Company issued the New Shares as a placement to sophisticated and professional investors which it announced to the ASX on 11 October 2017. The Placement has allowed the Company to raise additional funds under its placement capacity for further product enhancements on Mente Autism, manufacturing and purchase of additional inventory, investigating potential strategic initiatives and general working capital.

The New Shares are expected to commence normal trading on Thursday 26 October 2017.

-ends-

Neurotech International Ltd

ABN 73 610 205 402

Level 14, 191 St Georges Terrace

Perth, Western Australia 6060

www.neurotechinternational.com

About Neurotech

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech's primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente Autism and its associated platform, Neurotech is focused on the development and commercialisation of technological solutions for the diagnosis and treatment of such conditions, starting with autism.

Mente Autism is a clinical-quality EEG device that uses neurofeedback technology to help children with ASD. Designed for home use, Mente Autism helps relax the minds of children on the spectrum which in turns helps them to focus better and engage positively with their environment.

For more information about Neurotech and Mente Autism please visit:

<http://www.neurotechinternational.com>.

<http://www.mentetech.com>.

For more information please contact:

Matthew Wright

matt@nwrcommunications.com.au

Tel: +61 451 896 420